• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病神经纤维变性的分子机制及治疗干预

Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention.

作者信息

Iqbal K, Grundke-Iqbal I

机构信息

Chemical Neuropathology Laboratory, New York State Institute for Basic Research in Developmental Disabilities, Staten Island 10314, USA.

出版信息

Ann N Y Acad Sci. 1996 Jan 17;777:132-8. doi: 10.1111/j.1749-6632.1996.tb34411.x.

DOI:10.1111/j.1749-6632.1996.tb34411.x
PMID:8624075
Abstract

Microtubule-associated protein tau is abnormally hyperphosphorylated in the brain of patients with Alzheimer's disease (AD) and the abnormal tau is the major protein subunit of paired helical filaments (PHF). The abnormal phosphorylation of tau probably precedes its polymerization into PHF. The abnormal tau does not bind to tubulin, but competes with tubulin in binding to normal tau and thereby inhibits the assembly of microtubules in the affected neurons. The abnormal tau can be dephosphorylated enzymatically and by this way its microtubule assembly promoting activity can be restored. The activities of protein phosphatases might be decreased in the affected neurons in AD brain, allowing the abnormal hyperphosphorylation of tau. Neurofibrillary degeneration can probably be inhibited by increasing the activities of protein phosphatases in the brain of patients with Alzheimer's disease.

摘要

在阿尔茨海默病(AD)患者的大脑中,微管相关蛋白tau异常过度磷酸化,且异常的tau是双螺旋丝(PHF)的主要蛋白质亚基。tau的异常磷酸化可能先于其聚合成PHF。异常的tau不与微管蛋白结合,但在与正常tau结合时与微管蛋白竞争,从而抑制受影响神经元中微管的组装。异常的tau可通过酶促去磷酸化,从而恢复其促进微管组装的活性。在AD大脑中,受影响的神经元中蛋白磷酸酶的活性可能会降低,从而使tau发生异常的过度磷酸化。通过增加阿尔茨海默病患者大脑中蛋白磷酸酶的活性,可能会抑制神经原纤维变性。

相似文献

1
Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention.阿尔茨海默病神经纤维变性的分子机制及治疗干预
Ann N Y Acad Sci. 1996 Jan 17;777:132-8. doi: 10.1111/j.1749-6632.1996.tb34411.x.
2
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.神经原纤维变性及神经原纤维缠结形成的机制。
J Neural Transm Suppl. 1998;53:169-80. doi: 10.1007/978-3-7091-6467-9_15.
3
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.参与阿尔茨海默病神经纤维变性的激酶、磷酸酶及tau位点。
Eur J Neurosci. 2007 Jan;25(1):59-68. doi: 10.1111/j.1460-9568.2006.05226.x.
4
Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease.阿尔茨海默病中配对螺旋丝的泛素化与异常磷酸化
Mol Neurobiol. 1991;5(2-4):399-410. doi: 10.1007/BF02935561.
5
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.神经原纤维变性机制及药物治疗方法
J Neural Transm Suppl. 2000;59:213-22. doi: 10.1007/978-3-7091-6781-6_22.
6
Mechanism of neurofibrillary degeneration in Alzheimer's disease.阿尔茨海默病中神经原纤维变性的机制。
Mol Neurobiol. 1994 Aug-Dec;9(1-3):119-23. doi: 10.1007/BF02816111.
7
Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.阿尔茨海默病神经纤维变性的意义、机制及抑制该病变的治疗靶点
J Mol Neurosci. 2002 Aug-Oct;19(1-2):95-9. doi: 10.1007/s12031-002-0017-3.
8
Tau pathology in Alzheimer disease and other tauopathies.阿尔茨海默病及其他tau蛋白病中的tau蛋白病变
Biochim Biophys Acta. 2005 Jan 3;1739(2-3):198-210. doi: 10.1016/j.bbadis.2004.09.008.
9
Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.tau 异常过度磷酸化:部位、调节及神经原纤维变性的分子机制。
J Alzheimers Dis. 2013;33 Suppl 1:S123-39. doi: 10.3233/JAD-2012-129031.
10
Pharmacological approaches of neurofibrillary degeneration.神经纤维变性的药理学方法。
Curr Alzheimer Res. 2005 Jul;2(3):335-41. doi: 10.2174/1567205054367810.

引用本文的文献

1
Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease.多靶点:阿尔茨海默病的一种非常规药物研发策略
Front Aging Neurosci. 2022 Feb 9;14:837649. doi: 10.3389/fnagi.2022.837649. eCollection 2022.
2
Stimulation-dependent intraspinal microtubules and synaptic failure in Alzheimer's disease: a review.阿尔茨海默病中依赖刺激的脊髓内微管与突触功能障碍:综述
Int J Alzheimers Dis. 2012;2012:519682. doi: 10.1155/2012/519682. Epub 2012 Mar 8.
3
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.
糖原合酶激酶3抑制剂:阿尔茨海默病治疗的新希望
Int J Alzheimers Dis. 2011;2011:280502. doi: 10.4061/2011/280502. Epub 2011 Jun 30.
4
GSK-3beta is required for memory reconsolidation in adult brain.糖原合成酶激酶-3β是成年大脑记忆再巩固所必需的。
PLoS One. 2008;3(10):e3540. doi: 10.1371/journal.pone.0003540. Epub 2008 Oct 28.
5
Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.细胞周期蛋白依赖性激酶抑制剂可减轻尼曼-匹克C型小鼠的蛋白质过度磷酸化、细胞骨架损伤形成及运动缺陷。
Am J Pathol. 2004 Sep;165(3):843-53. doi: 10.1016/S0002-9440(10)63347-0.
6
Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition.阿尔茨海默病模型中c-Jun氨基末端激酶和p38的激活与淀粉样蛋白沉积有关。
J Neurosci. 2002 May 1;22(9):3376-85. doi: 10.1523/JNEUROSCI.22-09-03376.2002.
7
The role of dimerization in prion replication.二聚化在朊病毒复制中的作用。
Biophys J. 2002 Apr;82(4):1711-8. doi: 10.1016/S0006-3495(02)75523-9.